Business & Economics Books:

Data Science, AI, and Machine Learning in Drug Development

Click to share your rating 0 ratings (0.0/5.0 average) Thanks for your vote!

Format:

Hardback
$365.00
Available from supplier

The item is brand new and in-stock with one of our preferred suppliers. The item will ship from a Mighty Ape warehouse within the timeframe shown.

Usually ships in 3-4 weeks
Free Delivery with Primate
Join Now

Free 14 day free trial, cancel anytime.

Buy Now, Pay Later with:

4 payments of $91.25 with Afterpay Learn more

6 weekly interest-free payments of $60.83 with Laybuy Learn more

Availability

Delivering to:

Estimated arrival:

  • Around 22 Jul - 1 Aug using International Courier

Description

The confluence of big data, artificial intelligence (AI), and machine learning (ML) has led to a paradigm shift in how innovative medicines are developed and healthcare delivered. To fully capitalize on these technological advances, it is essential to systematically harness data from diverse sources and leverage digital technologies and advanced analytics to enable data-driven decisions. Data science stands at a unique moment of opportunity to lead such a transformative change. Intended to be a single source of information, Data Science, AI, and Machine Learning in Drug Research and Development covers a wide range of topics on the changing landscape of drug R & D, emerging applications of big data, AI and ML in drug development, and the build of robust data science organizations to drive biopharmaceutical digital transformations. Features Provides a comprehensive review of challenges and opportunities as related to the applications of big data, AI, and ML in the entire spectrum of drug R & D Discusses regulatory developments in leveraging big data and advanced analytics in drug review and approval Offers a balanced approach to data science organization build Presents real-world examples of AI-powered solutions to a host of issues in the lifecycle of drug development Affords sufficient context for each problem and provides a detailed description of solutions suitable for practitioners with limited data science expertise

Author Biography:

Harry Yang, Ph.D., is the Vice President and Head of Biometrics at Fate Therapeutics. He has 27 years of experience across all aspects of drug R & D, from early target discovery, through pre-clinical, clinical, translational science, and CMC programs to regulatory approval and post-approval lifecycle management. He played a pivotal role in the successful submissions of 5 biologics license appllications (BLAs) that ultimately led to marketing approvals of five biological products. He has published 8 statistical and data science books, 28 book chapters, over 100 peer-reviewed articles, and 3 industry white papers on diverse scientific, statistical, and data science subjects. He is a frequent invited speaker at national and international conferences. He has also developed statistical courses and conducted trainings at the United States Food and Drug Administration (FDA) and United States Pharmacopeia (USP).
Release date NZ
October 3rd, 2022
Audiences
  • Postgraduate, Research & Scholarly
  • Professional & Vocational
Contributor
  • Edited by Harry Yang
Illustrations
38 Tables, black and white; 64 Line drawings, black and white; 3 Halftones, black and white; 67 Illustrations, black and white
Pages
320
ISBN-13
9780367708078
Product ID
35732918

Customer reviews

Nobody has reviewed this product yet. You could be the first!

Write a Review

Marketplace listings

There are no Marketplace listings available for this product currently.
Already own it? Create a free listing and pay just 9% commission when it sells!

Sell Yours Here

Help & options

Filed under...